Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphom...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Persky, Daniel O., Miller, Thomas P., Unger, Joseph M., Spier, Catherine M., Puvvada, Soham, Stea, B. Dino, Press, Oliver W., Constine, Louis S., Barton, Kevin P., Friedberg, Jonathan W., LeBlanc, Michael, Fisher, Richard I.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2015
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4287635/
https://ncbi.nlm.nih.gov/pubmed/25395425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-584623
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars